Section Arrow
Quote
PHIO.NASDAQ
- Phio Pharmaceuticals Corp
Quotes are at least 15-min delayed:2026/03/22 18:39 EDT
Regular Hours
Last
 1.22
+0.04 (+3.39%)
Day High 
1.23 
Prev. Close
1.18 
1-M High
1.29 
Volume 
257.76K 
Bid
1.18
Ask
1.24
Day Low
1.18 
Open
1.18 
1-M Low
0.978 
Market Cap 
12.70M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.22 
20-SMA 1.15 
50-SMA 1.13 
52-W High 4.1899 
52-W Low 0.8127 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.45/-0.64
Enterprise Value
12.70M
Balance Sheet
Book Value Per Share
1.73
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AZTRAzitra0.2828+0.1067+60.59%-- 
LNAILunai Bioworks Inc.0.4685+0.0835+21.69%-- 
DRMADermata Therapeutics Inc1.46+0.25+20.66%0.09PE
GERNGeron Corp1.46-0.09-5.81%-- 
IBRXImmunityBio8.47-0.35-3.97%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programsare PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.